Maintenance of zilucoplan efficacy in patients with generalised myasthenia gravis up to 24 weeks: a model-informed analysis
Background: Clinical efficacy of zilucoplan has been demonstrated in a 12-week, placebo-controlled, phase III study in patients with acetylcholine receptor autoantibody-positive generalised myasthenia gravis (gMG). However, placebo-controlled zilucoplan data past 12 weeks are not available. Objectiv...
Збережено в:
| Автори: | , , , , , , , , , , , , , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
SAGE Publishing
2024-09-01
|
| Серія: | Therapeutic Advances in Neurological Disorders |
| Онлайн доступ: | https://doi.org/10.1177/17562864241279125 |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|